0001209191-21-012412.txt : 20210219 0001209191-21-012412.hdr.sgml : 20210219 20210219170045 ACCESSION NUMBER: 0001209191-21-012412 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210217 FILED AS OF DATE: 20210219 DATE AS OF CHANGE: 20210219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SHERMAN JEFFREY W CENTRAL INDEX KEY: 0001230482 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35238 FILM NUMBER: 21656886 MAIL ADDRESS: STREET 1: C/O IDM PHARMA, INC. STREET 2: 9 PARKER, SUITE 100 CITY: IRVINE STATE: CA ZIP: 92618 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Horizon Therapeutics Public Ltd Co CENTRAL INDEX KEY: 0001492426 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: CONNAUGHT HOUSE, 1ST FLOOR STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN STATE: L2 ZIP: 4 BUSINESS PHONE: 011-353-1-772-2100 MAIL ADDRESS: STREET 1: CONNAUGHT HOUSE, 1ST FLOOR STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN STATE: L2 ZIP: 4 FORMER COMPANY: FORMER CONFORMED NAME: Horizon Pharma plc DATE OF NAME CHANGE: 20140919 FORMER COMPANY: FORMER CONFORMED NAME: HORIZON PHARMA, INC. DATE OF NAME CHANGE: 20100520 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-17 0 0001492426 Horizon Therapeutics Public Ltd Co HZNP 0001230482 SHERMAN JEFFREY W C/O HORIZON THERAPEUTICS PLC CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD DUBLIN L2 4 IRELAND 0 1 0 0 EVP and Chief Medical Officer Ordinary Shares 2021-02-17 4 A 0 1965 0.00 A 80954 D Ordinary Shares 2021-02-17 4 F 0 871 87.17 D 80083 D Ordinary Shares 183634 I By Trust Performance Restricted Stock Units (PSUs) 2021-02-17 4 A 0 3931 0.00 A Ordinary Shares 3931 3931 D Performance Restricted Stock Units (PSUs) 2021-02-17 4 A 0 14512 0.00 A Ordinary Shares 14512 14512 D On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. Each PSU represents a contingent right to receive one ordinary share of the Issuer. On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met. Two-thirds of the ordinary shares subject to the PSUs vest on January 5, 2022 and the remaining one-third of the ordinary shares vest on January 5, 2023. /s/ Miles W. McHugh, Attorney-in-Fact 2021-02-19